Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GBP510

            Therapeutic Area: Infections and Infectious Diseases Product Name: GBP510

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: CEPI

            Deal Size: $26.7 million Upfront Cash: Undisclosed

            Deal Type: Funding March 10, 2021

            Details:

            CEPI will provide up to $14.2 million to support the adaptation of SK bioscience’s recombinant protein vaccine candidate (GBP510) for use against “variants of concern”, such as the B.1.351 variant first identified in South Africa.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GBP510

            Therapeutic Area: Infections and Infectious Diseases Product Name: GBP510

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: CEPI

            Deal Size: $10.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration December 09, 2020

            Details:

            CEPI will contribute up to $10 million towards the cost of a phase I/II study of a recombinant protein vaccine candidate (GBP510)—manufactured using a nanoparticle platform—and manufacture of clinical trial materials needed for phase I/II and phase III trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GX-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: GX-19

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 15, 2020

            Details:

            Genexine expects to obtain full data from a Phase I trial of its DNA vaccine GX-19 late this year or early next year, while starting a Phase IIa study within this year and concurrent Phase IIb and III trials in the first half of next year.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NVX-COV2373,Matrix-M

            Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Novavax

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 13, 2020

            Details:

            SK bioscience will manufacture the vaccine antigen component for use in the final drug product globally during the pandemic period. NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GX-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: GX-19

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 11, 2020

            Details:

            First domestic pharmaceutical company to have been approved for clinical phase 1/2a of GX-19, which is a DNA vaccine against COVID-19, by the Ministry of Food and Drug Safety.